StockNews.AI
BHC
StockNews.AI
194 days

Bausch Health Provides Update on Strategic Alternatives

1. Bausch Health is exploring the sale of Bausch + Lomb amid regulatory requests. 2. A private equity firm showed interest in acquiring Bausch + Lomb at a strong valuation.

2m saved
Insight
Article

FAQ

Why Bullish?

The interest from a private equity firm suggests potential liquidity and valuation increase, similar to past acquisitions in the industry boosting stock prices historically.

How important is it?

The potential sale of a major subsidiary could significantly influence BHC's future financial health and market position, given Bausch + Lomb's role in its portfolio.

Why Long Term?

A successful sale could reshape Baird's financial position and growth potential, leading to sustained price appreciation over time, akin to previous sales boosting parent company valuations.

Related Companies

BLCO
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a regulatory request: "In the second half of 2024, Bausch Health engaged with its financial advisors to work on various liability management alternatives. At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation.

Related News